Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00189748
Status:
COMPLETED
Last Update Posted:
2006-09-20
First Post:
2005-09-13
Brief Title:
A Study to Assess the Safety and Efficacy of a Tacrolimus New Oral Formulation MR4 in BMT Patients-Extension-
Sponsor:
Astellas Pharma Inc
Organization:
Astellas Pharma Inc
Study Overview
Official Title:
An Extension Study of the Patients Enrolled in Acute Graft Versus Host Disease GVHD Prophylaxis Study Protocol No FJ-506E-BT01 to Assess Safety and Efficacy of GVHD Prophylaxis of a Tacrolimus New Oral Formulation MR4
Status:
COMPLETED
Status Verified Date:
2006-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To assess safety and efficacy of the patients with MR4 therapy in GVHD prophylaxis study who are eligible for the administration after 100 days post transplant up to 1 year
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None